[{"from": "human", "value": "Could you provide a description of this molecule? [C][=C][N][Branch1][#Branch2][C][=Branch1][C][=S][N][=C][Ring1][#Branch1][N][C@][Branch1][P][C@H1][Branch1][=N][C@@H1][Branch1][=Branch2][C@H1][Branch1][Ring2][O][Ring1][Branch1][C][O][O][O][O].[Cl]"}, {"from": "gpt", "value": "The molecule is a member of the nucleoside class of cytotoxic drugs of which gemcitabine is the market leader. OSI Pharmaceuticals develops OSI-7836 as a next-generation gemcitabine. The anti-tumor activity of OSI-7836 appeares to be less schedule dependent than gemcitabine. It is also more active than ara-C (another clinically used nucleoside analog) in all nine models and more active than either paclitaxel or cisplatin in the two lung xenograft models tested. This drug shows no unexpected toxicities; those observed appeared to be similar to other nucleoside agents."}]